Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 692-695

  Gremmel, Thomas ^a   Kopp, Christoph W ^a   Eichelberger, Beate ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Leukocyte platelet aggregates; Platelet activation; Platelet reactivity; Sex

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; C REACTIVE PROTEIN; CLOPIDOGREL; CREATININE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6;

ADULT; AGED; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; HUMAN; LEUKOCYTE AGGREGATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROTEIN EXPRESSION; SEX DIFFERENCE; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE;

EID: 84910675628     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.095     Document Type: Article

References (20)

1. Vakili B.A., Kaplan R.C., Brown D.L. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation 2001, 104:3034-3038.
2. Vaccarino V., Parsons L., Every N.R., Barron H.V., Krumholz H.M. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N.Engl. J. Med. 1999, 341:217-225.
3. Milcent C., Dormont B., Durand-Zaleski I., Steg P.G. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database. Circulation 2007, 115:833-839.
4. Hanratty B., Lawlor D.A., Robinson M.B., Sapsford R.J., Greenwood D., Hall A. Sex differences in risk factors, treatment and mortality after acute myocardial infarction: an observational study. J.Epidemiol. Community Health 2000, 54:912-916.
5. Cheng C.I., Yeh K.H., Chang H.W., et al. Comparison of baseline characteristics, clinical features, angiographic results, and early outcomes in men vs women with acute myocardial infarction undergoing primary coronary intervention. Chest 2004, 126:47-53.
6. Berger J.S., Elliott L., Gallup D., et al. Sex differences in mortality following acute coronary syndromes. JAMA 2009, 302:874-882.
7. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C.W. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb. Haemost. 2009, 101:333-339.
8. Gremmel T., Xhelili E., Steiner S., Koppensteiner R., Kopp C.W., Panzer S. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: differences between peripheral and coronary angioplasty. Atherosclerosis 2014, 232:119-124.
9. Gremmel T., Eslam R.B., Koppensteiner R., Lang I.M., Panzer S. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovasc. Ther. 2013, 31:e40-e45.
10. Gremmel T., Durstberger M., Eichelberger B., Koppensteiner R., Kopp C.W., Panzer S. Human neutrophil alpha-defensins are associated with adenosine diphosphate-inducible neutrophil-platelet aggregate formation and response to clopidogrel in patients with atherosclerosis. Transl. Res. 2014, 10.1016/j.trsl.2014.03.006.
11. Badr Eslam R., Lang I.M., Kaider A., Panzer S. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition. Transl. Res. 2013, 161:414-420.
12. Linnemann B., Schwonberg J., Mani H., Prochnow S., Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J.Thromb. Haemost. 2008, 6:677-683.
13. Gremmel T., Calatzis A., Steiner S., et al. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?. Platelets 2010, 21:515-521.
14. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of invivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001, 104:1533-1537.
15. McEver R.P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb. Haemost. 2001, 86:746-756.
16. Diacovo T.G., deFougerolles A.R., Bainton D.F., Springer T.A. Afunctional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J.Clin. Invest. 1994, 94:1243-1251.
17. Chavakis T., Santoso S., Clemetson K.J., et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J.Biol. Chem. 2003, 278:45375-45381.
18. Simon D.I., Chen Z., Xu H., et al. Platelet glycoprotein ibalpha is a counter receptor for the leukocyte integrin Mac-1 (CD11b/CD18). J.Exp. Med. 2000, 192:193-204.
19. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C.W. Invivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb. Haemost. 2014, 111:474-482.
20. Kalb M.L., Potura L., Scharbert G., Kozek-Langenecker S.A. The effect of exvivo anticoagulants on whole blood platelet aggregation. Platelets 2009, 20:7-11.